Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases

Abstract

Glycopyrronium (GLY) and tiotropium (TIO) are inhaled LAMAs recommended for COPD patients in all GOLD groups (A,B,C&D).¹ GLY is effective and well tolerated in moderate-to-severe COPD patients, similar to TIO, and has faster onset and better bronchodilation in the first 4h after first dose.GLY and TIO efficacy was analyzed post hoc in patients by GOLD group (A,B,C&D), with data from 4 randomized controlled clinical trials, pooled and adjusted by mix-model. Patient classification (A&C, fewer symptoms; B&D, more symptoms) was based on baseline dyspnea index (BDI; ³7/<7)² and lung function (FEV₁; </> 50% predicted normal) not considering baseline exacerbation risk. Efficacy of GLY and TIO was measured by mean change from baseline at 12 weeks for trough FEV₁ (tFEV1), health status (SGRQ score) and dyspnea (TDI score).Out of 2599 patients (GLY=1628; TIO=971),30.6% and 26.7% were in the low-symptom groups A&C, with baseline mean(SD) BDI scores of 5.11(1.31) & 4.72(1.47) respectively, and baseline FEV₁ % predicted normal mean(SD) 62.54(7.94) & 40.50(6.07); 29.7% and 13.1% patients were in the high-symptom groups B&D, respectively, with BDI=8.18(1.29) & 7.95(1.23) and baseline FEV₁% predicted normal=64.66(8.58) & 41.85(5.68), respectively. Based on the least square means change from baseline at 12 weeks, GLY led to statistically significant and clinically relevant improvements in tFEV₁, dyspnea and health status in all GOLD groups; there was no significant difference between GLY and TIO.In conclusion, GLY improved lung function, dyspnea and health status in COPD patients in all GOLD groups, similar to TIO.1. GOLD 20152. Ozalevli et al 2006 J Eval Clin Pract 12; 532–538.


Rating:

Share or cite this content

Citations should be made in the following way:
Anthony D. D'Urzo (Toronto, Canada), Anthony D’Urzo, Giovanni Bader, Pablo Altman, Pankaj Goyal. Glycopyrronium significantly improves lung function, dyspnea and health status in COPD patients in all GOLD groups. Eur Respir J 2015; 46: Suppl. 59, 1009

Member's Comments

No comment yet.

Related content which might interest you: Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis Source: International Congress 2016 – COPD diagnosis and management Year: 2016 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 COPD: Influence of patients’ nutritive status on the exacerbations rate Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Source: Eur Respir J 2002; 19: 209-216 Year: 2002 LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Assessing COPD profiles and outcomes by dyspnoea severity Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Antagonism of substance P and perception of dyspnea in patients with COPD Source: Annual Congress 2013 –COPD mechanisms Year: 2013 QVA149 provides superior peak lung function in patients with COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Are COPD patients with chronic dyspnea and attending pulmonary rehabilitation treated with dual bronchodilatation or not? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification Source: International Congress 2014 – Asthma and COPD management Year: 2014 The impact of comorbidities on pulmonary rehabilitation outcomes in patients with COPD Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013